Foghorn Therapeutics (FHTX) Competitors $6.14 +0.01 (+0.08%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALTShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Pharvaris Intellia Therapeutics CureVac Aurinia Pharmaceuticals WAVE Life Sciences Calliditas Therapeutics AB (publ) Foghorn Therapeutics (NASDAQ:FHTX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Which has more volatility and risk, FHTX or HROW? Foghorn Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Which has preferable valuation & earnings, FHTX or HROW? Harrow has higher revenue and earnings than Foghorn Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M15.13-$86.62M-$1.36-4.51Harrow$199.61M6.93-$17.48M-$0.56-67.35 Do analysts prefer FHTX or HROW? Foghorn Therapeutics currently has a consensus price target of $12.13, suggesting a potential upside of 97.64%. Harrow has a consensus price target of $63.83, suggesting a potential upside of 69.25%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Foghorn Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer FHTX or HROW? In the previous week, Harrow had 17 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 17 mentions for Harrow and 0 mentions for Foghorn Therapeutics. Harrow's average media sentiment score of 0.45 beat Foghorn Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the news media. Company Overall Sentiment Foghorn Therapeutics Neutral Harrow Neutral Do insiders & institutionals hold more shares of FHTX or HROW? 61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 13.7% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is FHTX or HROW more profitable? Harrow has a net margin of -10.19% compared to Foghorn Therapeutics' net margin of -342.23%. Foghorn Therapeutics' return on equity of 0.00% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-342.23% N/A -27.28% Harrow -10.19%-25.01%-4.27% SummaryHarrow beats Foghorn Therapeutics on 10 of the 17 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$343.92M$2.92B$5.50B$9.47BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-4.5419.8028.1219.86Price / Sales15.13231.90424.0990.33Price / CashN/A40.8024.9928.17Price / Book-7.487.678.185.72Net Income-$86.62M-$55.16M$3.24B$257.70M7 Day Performance4.34%2.40%1.36%2.29%1 Month Performance29.98%14.48%8.68%13.82%1 Year Performance3.98%4.59%34.29%19.83% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics1.4218 of 5 stars$6.14+0.1%$12.13+97.6%+3.9%$343.92M$22.60M-4.54120HROWHarrow2.44 of 5 stars$35.62+2.0%$63.83+79.2%+43.5%$1.31B$199.61M-63.61180PAHCPhibro Animal Health4.0553 of 5 stars$31.54+2.4%$24.40-22.6%+57.8%$1.28B$1.02B40.441,940Positive NewsABCLAbCellera Biologics2.3255 of 5 stars$4.24+5.7%$8.75+106.4%+50.8%$1.27B$28.83M-7.57500Gap UpHigh Trading VolumeCOGTCogent Biosciences3.5527 of 5 stars$11.09+1.0%$18.00+62.3%+45.1%$1.26BN/A-6.0380Analyst ForecastGap UpHigh Trading VolumePHVSPharvaris1.4559 of 5 stars$23.80-5.3%$36.20+52.1%+26.6%$1.24BN/A-7.9130High Trading VolumeNTLAIntellia Therapeutics4.3174 of 5 stars$11.95+3.6%$33.37+179.2%-51.9%$1.24B$57.88M-2.28600Analyst RevisionCVACCureVac4.0764 of 5 stars$5.46flat$6.83+25.2%+46.9%$1.22B$579.18M5.93880AUPHAurinia Pharmaceuticals3.2744 of 5 stars$9.04+2.7%$11.50+27.2%+55.2%$1.22B$235.13M32.29300Positive NewsGap UpWVEWAVE Life Sciences4.6594 of 5 stars$7.84+1.8%$20.50+161.5%+42.8%$1.22B$108.30M-9.33240CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Harrow Competitors Phibro Animal Health Competitors AbCellera Biologics Competitors Cogent Biosciences Competitors Pharvaris Competitors Intellia Therapeutics Competitors CureVac Competitors Aurinia Pharmaceuticals Competitors WAVE Life Sciences Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
